Potential $11.4 Billion Value of Vertex’s Pain Drug Sparks Share Debate: Impact on Coin Market (VRTX)

• Vertex Pharmaceuticals’ stock advanced as analysts debate the potential of its pain drug, VX-548, which could be worth up to $11.4 billion in sales.
• The company beat forecasts in its first quarter report and has begun a rolling submission to the FDA for the approval of VX-548 in patients with moderate-to-severe acute pain.
• However, analysts are divided on whether the drug will succeed commercially, with estimates ranging from $400 million in peak sales to $11.4 billion in 2032 sales.

Vertex Pharmaceuticals’ stock rises as the company’s pain drug, VX-548, sparks debate among analysts. The drug could potentially generate up to $11.4 billion in sales.

Vertex Stock: Mature CF Franchise

Vertex is the market leader for cystic fibrosis treatments. In the first quarter, sales rose 13% to $2.69 billion. Ea... Read the full article for FREE at COINOTAG!